ViroGates A/S vs Abbott Laboratories: Fair Value & Quality
Both stocks run through our valuation models. Here is how ViroGates A/S (VIRO) and Abbott Laboratories (ABT) compare, as of Aug 11, 2026.
As of Aug 11, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: ViroGates A/S trades at DKK 10.10 versus a fair value of DKK 1.76 (-83%), while Abbott Laboratories trades at $109 versus $74.79 (-31%).
ViroGates A/S
VIRO.CO · DKK · Health Care
-83%
upside to fair value
overvalued
PriceDKK 10.10
Fair ValueDKK 1.76
Quality41/100
Abbott Laboratories
ABT · USD · Health Care
-31%
upside to fair value
overvalued
Price$109
Fair Value$74.79
Quality67/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
ViroGates A/SAbbott Laboratories
Valuation
—P/E (TTM)27.7×
1.61×P/S (TTM)3.89×
0.75×P/B3.36×
—EV/EBITDA15.1×
—PEG1.47×
Profitability
-114%Net margin14%
—Operating margin13%
-82%Return on equity12%
-31%Return on assets6%
Growth
8%Revenue growth (YoY)8%
-29.6%Avg. growth/yr (3Y)0.5%
-0.2%Avg. growth/yr (5Y)5.1%
Balance & size
0.17×Debt / equity0.19×
$14MMarket cap$175B
weakGrowth qualityhealthy
Abbott Laboratories leads: 4 to 5 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
ViroGates A/Sof which business quality 41 · market factors 42Abbott Laboratoriesof which business quality 66 · market factors 52
ProfitabilityMargins and returns on capital today
4
50
Quality GrowthAre margins and returns improving?
68
47
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
56
65
Low VolatilityCalm price path (market factor)
46
83
MomentumPrice trend over the last 3–12 months (market factor)
41
41
52W MomentumDistance to the 52-week high (market factor)
39
34
Net IssuanceBuybacks instead of dilution
0
84
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
ViroGates A/S
Asset-BasedDKK 1.40
1 of 1 models see the stock below the current price.
Abbott Laboratories
DCF Models$73.01
Earnings-Based$29.42
Dividend Discount$39.73
Multiples$70.72
Asset-Based$20.05
Growth DCF$67.02
Economic Profit$37.49
Growth Earnings$70.25
26 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
ViroGates A/S
Bear DKK 1.16Fair Value DKK 1.76Bull DKK 2.20
DKK 10.10 = current price (white tick)
Abbott Laboratories
Bear $51.84Fair Value $74.79Bull $94.43
$109 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
ViroGates A/S · Health Care
Quality score41 · below median
Fair value upside-83% · bottom 25%
Abbott Laboratories · Health Care
Quality score67 · Top 25%
Fair value upside-31% · below median
Bottom line
As of Aug 11, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: ViroGates A/S trades at DKK 10.10 versus a fair value of DKK 1.76 (-83%), while Abbott Laboratories trades at $109 versus $74.79 (-31%).
Abbott Laboratories has the higher quality score (67/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
